



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The prevalence of cannabis use among tobacco smokers: A systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050681
Article Type:	Protocol
Date Submitted by the Author:	01-Mar-2021
Complete List of Authors:	Skelton, Eliza; The University of Newcastle Faculty of Health and Medicine Denham, Alexandra; The University of Newcastle Faculty of Health and Medicine Lye, Alexie; The University of Newcastle Faculty of Health and Medicine Rich, Jane; The University of Newcastle Faculty of Health and Medicine Bonevski, Billie; The University of Newcastle Faculty of Health and Medicine
Keywords:	PUBLIC HEALTH, EPIDEMIOLOGY, Substance misuse < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title

The prevalence of cannabis use among tobacco smokers: A systematic review protocol

Authors, Affiliations, highest academic, qualification and emails

Eliza Skelton^{1,2}, PhD (Psychiatry), Eliza.Skelton@newcastle.edu.au

Alexandra Denham^{1,2} PhD (Behavioural Medicine), Alexandra.Denham@newcastle.edu.au

Alexie Lye^{1,2} Bachelor of Nutrition and Dietetics, Alexie.Lye@newcastle.edu.au

Jane Rich^{1,2}PhD, Jane.Rich@newcastle.edu.au

Billie Bonevski^{1,2} PhD (Behavioural Science), Billie.Bonevski@newcastle.edu.au

Institutional Affiliations

¹ The University of Newcastle, Faculty of Health and Medicine, School of Medicine and Public Health, 1 University Drive, Callaghan, NSW 2308, Australia.

² Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia.

***Corresponding author:** Eliza Skelton, Level 5 McAuley Centre, Calvary Mater Hospital, Waratah NSW 2298, Australia. Telephone: 02-4033-5711, Fax: 02-40335692, Email: Eliza.Skelton@newcastle.edu.au

Manuscript word count:

Manuscript number of reference: 37

Tables: 1

Figures: 0

Supplementary Tables and Figures: 0

21 Abstract

22 **Introduction:** Understanding the prevalence of cannabis use among tobacco smokers has
23 important implications for research in terms of intervention effectiveness and measurement in
24 smoking cessation trials. The co-use of these substances also has important implications for
25 health service planning, specifically ensuring appropriate and adequate clinical treatment. To
26 date there have been no synthesis of the literature on the prevalence of tobacco and cannabis
27 co-use in adult clinical populations. Improved understanding of the current prevalence, route
28 of administration, and specific subpopulations with the highest rates of tobacco and cannabis
29 co-use will support future intervention development. We aim to provide a pooled estimate of
30 the percentage of smokers who report using cannabis and to examine the prevalence of co-use
31 by socio-demographic characteristics.

32 **Methods and Analysis:** We will conduct a systematic review using six scientific databases
33 (CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural
34 Sciences Collection, Scopus). Peer-reviewed journal articles published in English that report
35 on tobacco and cannabis use will be included. Rates of co-use (simultaneous or sequentially)
36 and routes of administration will be assessed. Use in populations groups will be described.
37 Quality assessments will be conducted for all included studies. Data will be synthesised using
38 a narrative approach.

39 **Ethics and Dissemination:** This review is based upon previously published data and
40 therefore ethical approval or written informed consent will not be required. It is the intention
41 of the research team to disseminate the results of the systematic review as a peer reviewed
42 publication and conference presentations.

43 **Systematic review registration:** CRD42020194051.

44 **Keywords:** Public Health, Epidemiology, Substance Misuse

1
2
3 45 ***Strengths and limitations:***
4

- 5 46 • Utilising the gold standard or meta-analysis, the proposed review will collate multiple
6
7
8 47 studies to provide the first pooled prevalence of tobacco and cannabis co-use.
9
10 48 • This review will also provide important information on the sub-groups that require
11
12
13 49 targeted intervention.
14
15 50 • There are several limitations that need to be noted, the first, is publication bias and the
16
17 51 second is that if the included studies measures are too heterogeneous, we will not be
18
19 52 able to complete a meta-analysis.
20
21

22 53
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

54 Introduction

55 Tobacco smoking continues to be a leading cause of preventable disease and death.
56 An estimated 1.1 billion people continue to smoke tobacco. Over the past three decades the
57 prevalence of tobacco smoking has been increasing in low- and middle-income countries
58 (LMIC) [1] where an inverse relationship is seen in high income countries (HIC) where
59 significant declines are noted. For example, in LMIC, the adult smoking prevalence rate has
60 increased from 12.4% to 22.8% in Rwanda, from 33.8% to 39.5% in Indonesia, and from
61 16% to 40.4% in Zambia[2]. While in HIC, the tobacco smoking prevalence has reduced
62 from 30.1% to 13.7% in the US[3], from 31% to 14.0% in Australia[4], 30% to 14.2% in
63 New Zealand[5], and 33% to 14.1% in the United Kingdom[6]. The decline in the prevalence
64 of tobacco smoking appears to be less apparent among specific sub-populations in HIC[7].
65 People who have a substance use disorder or are in treatment for substance misuse[8], people
66 with a severe mental illness[9], people who are homeless or at risk of homelessness[10] are
67 found to have smoking rates 2-6 times higher than the general population.

68 Cannabis is another commonly utilised substance[11]. Global estimates suggest that
69 the number of cannabis users has increased in many countries, as has the treatment for
70 cannabis use disorder[12]. Changing regulatory environments and the legalisation of cannabis
71 in some countries, and decreasing perceptions of risk associated with cannabis use[13, 14],
72 have been viewed to contribute to this recently increase in use[15-17]. Other contributors to
73 the increased use of cannabis include socio-demographic and environmental risk factors.
74 These factors may differ in between LMIC compared to high-income countries yet no review
75 to date has examine this relationship.

76 Co-use can refer to concurrent use of both tobacco and cannabis, individually
77 (sequentially), and to co-administration, or the use of the two substances at the same time, eg
78 cannabis and tobacco leaf mixed within roll-your-own cigarettes (concurrent)[18]. Patterns of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

tobacco and cannabis co-use appear to differ by country. A 2018 International Tobacco Control Survey identified that Canada, followed by the US (29.1%), England (21.6%), and Australia (21.4%) had the highest rates of tobacco and cannabis co-use [19]. There are limited studies examining tobacco and cannabis co-use in LMIC. Tobacco and cannabis co-use is often missed in population prevalence surveys[13].

Previous reviews on tobacco and cannabis co-use have examined mechanisms of initiation [20, 21] toxicant exposure[22], and co-administered products (such as blunts or spliffs) [23]. While other reviews have focused specifically on certain populations such as adolescents and young adults [24]. One important gap in the growing literature is a comprehensive pooled prevalence estimate of tobacco and cannabis co-use. Synthesising the existing data is important to understand the extent to which tobacco and cannabis co-use is occurring.

There appears to be an increased physiological effect of both substance when used together. The mechanisms underlying the co-use of tobacco and cannabis have been identified as shared genetic factors, environmental factors (peer influences; availability; younger age), and economic factors (lower socio-economic factors)[20]. More recently, another possible factor influencing co-use of tobacco and cannabis is the common route of administration e.g. smoking/ inhalation of both substances[18]. To date, only one review has examined route of administration and only focused on combustible forms of tobacco and cannabis co-use [23]. A synthesis of the literature that includes all possible routes of administration would fill this gap in the literature.

Compared to other substances, cannabis use among tobacco smokers appears to be more common than the co-use of other substances that occur at a remarkably reduced rate such as alcohol (33.3-45.7%), cocaine (37.5%-42.9%), stimulants (30-51.7%) and hallucinogens (35.6-41.7%)[25-27]. The relationship between tobacco and cannabis use is

104 synergistic in that tobacco use increases cannabis dependence symptoms [18, 28] and
105 precipitates cannabis relapse [29] and similarly cannabis use increases the likelihood of
106 nicotine dependence [30] and decreases tobacco cessation [31]. Given this, people who co-
107 use both tobacco and cannabis are at greater risk for serious for serious health and
108 psychosocial problems [21]. Co-use is associated with increased risks of toxicant exposure,
109 poorer physical and mental functioning [23].

110 Understanding and accounting for current cannabis use among participants involved
111 in smoking cessation research is important as it may have an impact on the intervention effect
112 but also the measurement effect. If smokers are recruited into a smoking cessation
113 intervention but their cannabis use is not addressed, then relapse to tobacco smoking is likely
114 if they regularly mixed their tobacco with cannabis. Similarly, since cannabis use is detected
115 in carbon monoxide breath analysis, this method of biochemical verification of tobacco
116 smoking status may be inaccurate. Therefore, an alternate biochemical method such as serum
117 or salivary cotinine may be preferable for self-reported tobacco smokers who utilise cannabis
118 [32].

119 Only limited research has described the demographic and clinical characteristics of
120 people who use both tobacco and cannabis. These studies predominately focussed on young
121 people who use these substances. Demographic characteristics such as older adolescents[33,
122 34] another found that people who co-use tobacco and cannabis were younger than tobacco-
123 only users[24], of male gender, and ethnicity. A synthesis of the current literature is critical
124 for the development of an evidence base foundation for developing future randomised
125 controlled trials. This review will provide the first synthesis of the literature and provide
126 pivotal information for specific countries to influence the development of socially and
127 culturally appropriate interventions to further the evidence base.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

There is a clear need for an improved understanding as to the co-use of tobacco and cannabis use as this will have practical implications in the design of smoking cessation studies. Our review will ask the following questions 1. What is the percentage of smokers who report also using cannabis; 2. What is the nature of co-use of tobacco and cannabis (e.g. mixing together or smoking at different times, including routes of administration); and 3. What is the prevalence of co-use tobacco and cannabis by socio-demographic characteristics (age; gender; country – low and high income; clinical characteristics such as mental health diagnosis and substance use disorder).

METHODS

Study design

We will complete a systematic review examining the prevalence of cannabis use among tobacco smokers generally and by specific socio-demographic and clinical characteristics as well as the nature of the use of these substances (whether concurrently or individually). This review will be conducted in line with the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines. This review has been registered with PROSPERO (insert ID number). Any variations to the originally registered protocol will be submitted as an amendment to PROSPERO and indicated in the review publication.

Study criteria

Study designs: we will include the following study designs: cohort, cross-sectional, observational, baseline assessments/ surveys of intervention studies, national reports. We will exclude published editorials, letters, or conference proceedings (including abstracts), qualitative studies, thesis dissertations, and studies quoting the incidence rate rather than prevalence. Further, we will not use genetic epidemiological studies that report prevalence estimates in family members of individuals who use tobacco and cannabis.

Study populations and participants: Person-level data will be included from any adult population (aged > 18 years and older) including but not limited to educational populations (for example university populations), forensic or correctional populations, treatment seeking populations (people receiving treatment for substance use disorders or mental health conditions, oncological conditions, and other chronic diseases). We will include all routes of administration of tobacco use including alternate nicotine devices such as vaporisers.

Outcomes: We will include studies that report primary data on the prevalence of tobacco and cannabis use (such as total number of participants and percentages or proportions). Given that there is no standard assessment tool of tobacco and cannabis co-use we will include all measures as documented in the literature. For example, separate items that measure cannabis and tobacco use: “Do you currently smoke any tobacco products?” with response options i) yes, at least once a week; ii) yes, less often than once week; iii) no, not at all”; “During the past 30 days, on how many days did you use cannabis?”; “How many times is cannabis used per day on using days”. Co-use has been defined in several recent US studies as the use of both substances within the past 30 days.

Additional eligibility criteria: Only articles that are published in English and that have been published in peer reviewed journals will be included [9].

Search Strategy

The search will be conducted in six databases: CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural Sciences Collection, Scopus, using keywords consistent across all databases and Medical Subject Headings (MeSH) applicable to specific databases. The Medline search terms are outlined in Table 1. Each search term is related to an overarching theme that map largely to the review aims (tobacco use and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

cannabis use). It should be noted that the search terms have been developed with guidance from the Cochrane Public Health and Tobacco Addiction Group search terms.

Table 1. Search themes and terms

Theme	Search Terms
Study design	Epidemiology Cohort stud* OR Cohort analysis Cross-sectional stud* OR Cross-section analysis OR Observational analysis OR Prevalence OR Longitudinal
Tobacco use	tobacco OR nicotine OR smok* OR vap* OR cigar*
Cannabis use	cannabis OR cannabinoid* OR marijuana OR weed OR hash*

Screening

Two research assistants (AD, AL) will screen all titles and abstracts using the previously described inclusion criteria overseen by the post-doctoral research academic (ES). Any disagreements will be discussed between the post-doctoral research academic (ES) and the two research assistants (AD, AL). If a resolution cannot be found, the senior review author (BB) will hold a discussion until a resolution is found. The two RAs (AD, AL) completing 50% each. Again, any disagreements will be discussed between the post-doctoral research academic (ES) and the research assistants. All title, abstract, and full-text data screening will be completed using the Covidence online software v1919 73d6c782.

Data extraction

The team will develop a data extraction form based on the aims of the study. The data extraction form will include: country, year of publication, author, sample size, gender,

192 tobacco use prevalence (lifetime, last 12 months, current), cannabis use prevalence (lifetime,
193 last 12 months, current), co-use prevalence, and routes of administration will be extracted for
194 each paper. The co-use prevalence and calculated 95% confidence intervals (CI) for each
195 estimate will be extracted. For papers reporting intervention studies, or for paper reporting
196 repeated measures over time, we will use the prevalence data from the baseline assessment.
197 Two post-doctoral research academics (ES and JR) will extract data from all included
198 publications. Any disagreements will be discussed between all the two review authors. If a
199 resolution cannot be found, the senior review author (BB) will be consulted in order to
200 determine a resolution. Data will be extracted using the Covidence software.

201 **Quality assessment**

202 All cohort, cross-sectional, and case-control studies will be appraised according to
203 Newcastle-Ottawa Quality Assessment Scale for cohort and case-control studies (adapted for
204 cross-sectional studies). Using the tool each study is judged on eight items, that can be
205 categorised into three further groups: 1. The selection of the study groups, 2. The
206 comparability of the groups, and 3. The ascertainment of either the exposure or outcome of
207 interest for case-control or cross-sectional studies respectively. Articles will not be excluded
208 based upon their score on the quality appraisal tool. Quality scores will guide judgement of
209 the methodological quality of the trial and reliability of the findings.

210 The risk of bias (quality) of all studies meeting the inclusion criteria will be formally
211 assessed by ES and JR. Disagreements will be resolved by discussion with the senior review
212 author (BB). Ratings will be presented in a table and will be used to inform the narrative
213 synthesis.

214 ***Assessment of study heterogeneity.*** Heterogeneity will be examined using visual
215 inspection of box plots, forest plots and using the I² statistic. Where there is evidence of high
216 heterogeneity (I²>75%), heterogeneity will be explored via subgroup analyses according to

trial intervention and population characteristics. Funnel plots will be generated by statistical software to enable the assessment of publication bias.

Grading the strength of evidence. As recommended by the Cochrane Handbook for Systematic Reviews of Interventions, the overall quality of evidence of the outcomes (tobacco and cannabis co-use prevalence) will be presented using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. This involves a within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias. The overall quality of evidence will be rated at four levels: high, moderate, low and very low.

ES and JR will assess the quality of evidence using the GRADE tool and will present the findings to the investigator team. The team will discuss the assessment and modify the reported strength of recommendations.

Data synthesis

Depending on the outcome measure employed by studies, pooled estimates by lifetime use, 12-months, and current use will be calculated. If studies have used similar definitions and measures, cannabis prevalence plots including the associated confidence intervals for each study will be presented. If there are national prevalence estimates for cannabis use, we will examine the difference between the study and the national prevalence.

In order to obtain the national smoking prevalence rates, official country statistics websites and the World Health Organisation Health Observatory Data Repository[35] will be consulted and the prevalence data extracted. If the national cannabis prevalence estimates are not available for all included countries for all years in which included studies were completed, we will report this information descriptively in the results section.

Included studies will be examined by socio-demographic and clinical characteristics to provide individual prevalence estimates and distributions. These will include socio-

demographic characteristics such as age, gender, country, nationality and Indigeneity. These will also include clinical characteristics such as mental health diagnosis as per the clinical diagnostic handbooks and tools (such as the Diagnostic and Statistical Manual of mental disorders (DSM)[36] or the International Classification of Disease (ICD)[37]) including substance use disorders and clinical populations such as individuals receiving treatment from addiction treatment or mental health services, as well as those with cardiovascular disease, diabetes, or cancer.

Patient and Public Involvement

No patients involved.

Study Status

At the time of submission of this protocol, the authors had completed screening of titles, abstracts, and full-texts, and were beginning data extraction and quality assessment.

DISCUSSION

The co-use of tobacco and cannabis and the sub-population who are most likely to co-use these substances are important considerations for intervention planning. This systematic review will provide pooled prevalence estimates of cannabis use among tobacco smokers. This study will report on tobacco and cannabis co-use by specific socio-demographics and clinical characteristics to provide a more in-depth examination and synthesis of the available data. This study will also provide the routes of administration of tobacco and cannabis co-use as this is an important aspect when developing behavioural interventions for cessation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

263 **Abbreviations**

264 DSM, Diagnostic and Statistical Manual of mental disorders

265 ICD, International Classification of Disease

266 GRADE, Grading of Recommendations Assessment, Development, and Evaluation

267 MeSH, Medical Subject Headings

268 PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses

269 RA, Research Assistant

270 **Declarations**

271 **Ethics approval and consent to participate:** Ethics approval was not required for this
272 systematic review.

273 **Consent for publication:** Consent was not required for this systematic review

274 **Availability of data and materials:** Not applicable

275 **Competing interests:** The authors declare that they have no competing interests.

276 **Funding:** None to report.

277 **Author contributions:** ES prepared the systematic review protocol and drafted the
278 manuscript. All authors provided feedback on the protocol and manuscript, and read and
279 approved the final manuscript.

280 **Acknowledgements:** Not applicable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Anderson, C.L., H. Becher, and V. Winkler, *Tobacco control progress in low and middle income countries in comparison to high income countries*. International journal of environmental research and public health, 2016. **13**(10): p. 1039.

2. Brathwaite, R., et al., *A systematic review of tobacco smoking prevalence and description of tobacco control strategies in Sub-Saharan African countries; 2007 to 2014*. PloS one, 2015. **10**(7): p. e0132401.

3. Centers for Disease Control and Prevention. *Smoking & Tobacco Use: Current Cigarette Smoking among Adults in the United States*. 2020; Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm.

4. Australian Institute of Health and Welfare. *National Drug Strategy Household Survey 2019*. 2019; Available from: <https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2019/contents/table-of-contents>.

5. New Zealand Ministry of Health. *Key Indicators 2020*. 2020; Available from: https://minhealthnz.shinyapps.io/nz-health-survey-2018-19-annual-data-explorer/_w_262e575b/#!/key-indicators.

6. United Kingdom Government. *Adult smoking habits in the UK: 2019*. 2020; Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/adultsmokinghabitsingreatbritain/2019#characteristics-of-current-cigarette-smokers-in-the-uk>.

7. Bonevski, B., et al., *No smoker left behind: it's time to tackle tobacco in Australian priority populations*. Med J Aust, 2017. **207**(4): p. 141-142.

- 305 8. Guydish, J., et al., *An international systematic review of smoking prevalence in*
306 *addiction treatment*. Addiction, 2016. **111**(2): p. 220-230.
- 307 9. Dickerson, F., et al., *Cigarette smoking among persons with schizophrenia or bipolar*
308 *disorder in routine clinical settings, 1999–2011*. Psychiatric services, 2013. **64**(1): p.
309 44-50.
- 310 10. Arnsten, J.H., et al., *Smoking behavior and interest in quitting among homeless*
311 *smokers*. Addictive behaviors, 2004. **29**(6): p. 1155-1161.
- 312 11. World Health Organization. *The health and social effects of nonmedical cannabis use*.
313 2021; Available from:
314 https://www.who.int/substance_abuse/publications/msbcannabis.pdf.
- 315 12. Degenhardt, L., et al., *The global epidemiology and contribution of cannabis use and*
316 *dependence to the global burden of disease: results from the GBD 2010 study*. PloS
317 one, 2013. **8**(10): p. e76635.
- 318 13. Weinberger, A.H., et al., *Cigarette smoking quit ratios among adults in the USA with*
319 *cannabis use and cannabis use disorders, 2002–2016*. Tobacco control, 2020. **29**(1):
320 p. 74-80.
- 321 14. Weinberger, A.H., et al., *Trends in cannabis use disorder by cigarette smoking status*
322 *in the United States, 2002–2016*. Drug and alcohol dependence, 2018. **191**: p. 45-51.
- 323 15. Maxwell, J.C. and B. Mendelson, *What do we know about the impact of the laws*
324 *related to marijuana?* Journal of addiction medicine, 2016. **10**(1): p. 3.
- 325 16. Mauro, C.M., et al., *Impact of medical marijuana laws on state-level marijuana use*
326 *by age and gender, 2004–2013*. Prevention Science, 2019. **20**(2): p. 205-214.
- 327 17. Pacek, L.R., P.M. Mauro, and S.S. Martins, *Perceived risk of regular cannabis use in*
328 *the United States from 2002 to 2012: differences by sex, age, and race/ethnicity*. Drug
329 and alcohol dependence, 2015. **149**: p. 232-244.

1
2
3 330 18. Agrawal, A. and M.T. Lynskey, *Tobacco and cannabis co-occurrence: does route of*
4
5 331 *administration matter?* Drug and alcohol dependence, 2009. **99**(1-3): p. 240-247.
6
7
8 332 19. Gravelly, S., et al., *International differences in patterns of cannabis use among adult*
9
10 333 *cigarette smokers: findings from the 2018 ITC Four Country Smoking and Vaping*
11
12 334 *Survey*. International Journal of Drug Policy, 2020. **79**: p. 102754.
13
14 335 20. Agrawal, A., A.J. Budney, and M.T. Lynskey, *The co-occurring use and misuse of*
15
16 336 *cannabis and tobacco: a review*. Addiction, 2012. **107**(7): p. 1221-1233.
17
18 337 21. Rabin, R.A. and T.P. George, *A review of co-morbid tobacco and cannabis use*
19
20 338 *disorders: Possible mechanisms to explain high rates of co-use*. The American journal
21
22 339 *on addictions*, 2015. **24**(2): p. 105-116.
23
24 340 22. Meier, E. and D.K. Hatsukami, *A review of the additive health risk of cannabis and*
25
26 341 *tobacco co-use*. Drug and Alcohol Dependence, 2016. **166**: p. 6-12.
27
28 342 23. Schauer, G.L., Z.R. Rosenberry, and E.N. Peters, *Marijuana and tobacco co-*
29
30 343 *administration in blunts, spliffs, and mulled cigarettes: A systematic literature review*.
31
32 344 *Addictive Behaviors*, 2017. **64**: p. 200-211.
33
34 345 24. Ramo, D.E., H. Liu, and J.J. Prochaska, *Tobacco and marijuana use among*
35
36 346 *adolescents and young adults: a systematic review of their co-use*. Clinical
37
38 347 *psychology review*, 2012. **32**(2): p. 105-121.
39
40 348 25. Barrett, S.P., C. Darredeau, and R.O. Pihl, *Patterns of simultaneous polysubstance use*
41
42 349 *in drug using university students*. Human Psychopharmacology: Clinical and
43
44 350 *Experimental*, 2006. **21**(4): p. 255-263.
45
46 351 26. Richter, K.P., et al., *A population-based study of cigarette smoking among illicit drug*
47
48 352 *users in the United States*. Addiction, 2002. **97**(7): p. 861-869.
49
50
51
52
53
54
55
56
57
58
59
60

- 353 27. Correa, J.B., et al., *Co-occurring Use of Cannabis and Tobacco and the Presence of*
354 *Acute Respiratory Symptoms among Young Adult Light and Intermittent Smokers.*
355 *Substance Use & Misuse*, 2020. **55**(13): p. 2129-2137.
- 356 28. Ream, G.L., et al., *Smoking tobacco along with marijuana increases symptoms of*
357 *cannabis dependence.* *Drug and alcohol dependence*, 2008. **95**(3): p. 199-208.
- 358 29. Haney, M., et al., *Predictors of marijuana relapse in the human laboratory: robust*
359 *impact of tobacco cigarette smoking status.* *Biological psychiatry*, 2013. **73**(3): p.
360 242-248.
- 361 30. Okoli, C.T., et al., *Adolescents' self-defined tobacco use status, marijuana use, and*
362 *tobacco dependence.* *Addictive behaviors*, 2008. **33**(11): p. 1491-1499.
- 363 31. Ford, D.E., H.T. Vu, and J.C. Anthony, *Marijuana use and cessation of tobacco*
364 *smoking in adults from a community sample.* *Drug and alcohol dependence*, 2002.
365 **67**(3): p. 243-248.
- 366 32. Van Vunakis, H., et al., *Relative sensitivity and specificity of salivary and serum*
367 *cotinine in identifying tobacco-smoking status of self-reported nonsmokers and*
368 *smokers of tobacco and/or marijuana.* *Archives of Environmental Health: An*
369 *International Journal*, 1989. **44**(1): p. 53-58.
- 370 33. Suris, J.-C., et al., *Some go without a cigarette: characteristics of cannabis users who*
371 *have never smoked tobacco.* *Archives of pediatrics & adolescent medicine*, 2007.
372 **161**(11): p. 1042-1047.
- 373 34. Victoir, A., et al., *Association of substance-use behaviours and their social-cognitive*
374 *determinants in secondary school students.* *Health education research*, 2007. **22**(1): p.
375 81-94.
- 376 35. World Health Organization, *Global health observatory data repository.* 2013.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

377 36. Association, A.P., *Diagnostic and statistical manual of mental disorders (DSM-5®)*.
378 2013: American Psychiatric Pub.
379 37. World Health Organization, *International Classification of Disease—Ninth*
380 *revision(ICD-9)*. Weekly Epidemiological Record= Relevé épidémiologique
381 hebdomadaire, 1988. **63**(45): p. 343-344.
382

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page #
ADMINISTRATIVE INFORMATION			
Title:			1
Identification	1a	Identify the report as a protocol of a systematic review	
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	1 & 14
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	14
Sponsor	5b	Provide name for the review funder and/or sponsor	14
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	14
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6-7
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	7-8
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	8

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	9
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	9-10
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	9-10
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	9-10
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	11
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	11
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	10
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	N/A
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	N/A
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11-12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	11
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	N/A
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	11

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

The prevalence of cannabis use among tobacco smokers: A systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050681.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Mar-2022
Complete List of Authors:	Skelton, Eliza; The University of Newcastle Faculty of Health and Medicine Rich, Jane; The University of Newcastle Faculty of Health and Medicine Handley, Tonelle; University of Newcastle, Bonevski, Billie; Flinders University College of Medicine and Public Health
Primary Subject Heading:	Addiction
Secondary Subject Heading:	Public health, Smoking and tobacco
Keywords:	PUBLIC HEALTH, EPIDEMIOLOGY, Substance misuse < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title

The prevalence of cannabis use among tobacco smokers: A systematic review protocol

Authors, Affiliations, highest academic, qualification and emails

Eliza Skelton¹, PhD (Psychiatry), Eliza.Skelton@newcastle.edu.au

Jane Rich¹ PhD (Public Health), Jane.Rich@newcastle.edu.au

Tonelle Handley¹ PhD (Psychiatry), Tonelle.Handley@newcastle.edu.au

Billie Bonevski² PhD (Behavioural Science), billie.bonevski@flinders.edu.au

Institutional Affiliations

¹ The University of Newcastle, Faculty of Health and Medicine, School of Medicine and Public Health, 1 University Drive, Callaghan, NSW 2308, Australia.

² Flinders University, Bedford Park, South Australia, 5042

***Corresponding author:** Prof Billie Bonevski PhD (Behavioural Science), billie.bonevski@flinders.edu.au College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042.

Manuscript word count: 2581

Manuscript number of reference: 37

Tables: 1

Figures: 0

Supplementary Tables and Figures: 0

Abstract

Introduction: Understanding the prevalence of cannabis use among tobacco smokers has important implications for research in terms of intervention effectiveness and measurement in smoking cessation trials. The co-use of these substances also has important implications for health service planning, specifically ensuring appropriate and adequate clinical treatment. To date there have been no synthesis of the literature on the prevalence of tobacco and cannabis co-use in adult clinical populations. Improved understanding of the current prevalence, route of administration, and specific subpopulations with the highest rates of tobacco and cannabis co-use will support future intervention development. We aim to provide a pooled estimate of the percentage of smokers who report using cannabis and to examine the prevalence of co-use by socio-demographic characteristics.

Methods and Analysis: We will conduct a systematic review using six scientific databases (CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural Sciences Collection, Scopus). Peer-reviewed journal articles published in English that report on tobacco and cannabis use will be included. Rates of co-use (simultaneous or sequentially) and routes of administration will be assessed. Use in populations groups will be described. Quality assessments will be conducted for all included studies. Data will be synthesised using a narrative approach.

Ethics and Dissemination: This review is based upon previously published data and therefore ethical approval or written informed consent will not be required. It is the intention of the research team to disseminate the results of the systematic review as a peer reviewed publication and conference presentations.

Systematic review registration: CRD42020194051.

Keywords: Public Health, Epidemiology, Substance Misuse

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations:

- Utilising the gold standard or meta-analysis, the proposed review will collate multiple studies to provide the first pooled prevalence of tobacco and cannabis co-use.
- This review will also provide important information on the sub-groups that require targeted intervention.
- There are several limitations that need to be noted, the first, is publication bias and the second is that if the included studies measures are too heterogeneous, we will not be able to complete a meta-analysis.

53 Introduction

54 Tobacco smoking continues to be a leading cause of preventable disease and death.
55 An estimated 1.1 billion people continue to smoke tobacco. Over the past three decades the
56 prevalence of tobacco smoking has been increasing in low- and middle-income countries
57 (LMIC) [1] where an inverse relationship is seen in high income countries (HIC) where
58 significant declines are noted. For example, in LMIC, the adult smoking prevalence rate has
59 increased from 12.4% to 22.8% in Rwanda, from 33.8% to 39.5% in Indonesia, and from
60 16% to 40.4% in Zambia[2]. While in HIC, the tobacco smoking prevalence has reduced
61 from 30.1% to 13.7% in the US[3], from 31% to 14.0% in Australia[4], 30% to 14.2% in
62 New Zealand[5], and 33% to 14.1% in the United Kingdom[6]. The decline in the prevalence
63 of tobacco smoking appears to be less apparent among specific sub-populations in HIC[7].
64 People who have a substance use disorder or are in treatment for substance misuse[8], people
65 with a severe mental illness[9], people who are homeless or at risk of homelessness[10] are
66 found to have smoking rates 2-6 times higher than the general population.

67 Cannabis is another commonly utilised substance[11]. Global estimates suggest that
68 the number of cannabis users has increased in many countries, as has the treatment for
69 cannabis use disorder[12]. Changing regulatory environments and the legalisation of cannabis
70 in some countries, and decreasing perceptions of risk associated with cannabis use[13, 14],
71 have been viewed to contribute to this recently increase in use[15-17]. Other contributors to
72 the increased use of cannabis include socio-demographic and environmental risk factors [18]
73 including the COVID-19 pandemic [19]. These factors may differ in between LMIC
74 compared to high-income countries yet no review to date has examine this relationship.

75 Co-use can refer to concurrent use of both tobacco and cannabis, individually
76 (sequentially), and to co-administration, or the use of the two substances at the same time, eg
77 cannabis and tobacco leaf mixed within roll-your-own cigarettes (concurrent)[20]. Patterns of

78 tobacco and cannabis co-use appear to differ by country. A 2018 International Tobacco
79 Control Survey identified that Canada, followed by the US (29.1%), England (21.6%), and
80 Australia (21.4%) had the highest rates of tobacco and cannabis co-use [21]. There are
81 limited studies examining tobacco and cannabis co-use in LMIC. Tobacco and cannabis co-
82 use is often missed in population prevalence surveys[13].

83 Previous reviews on tobacco and cannabis co-use have examined mechanisms of
84 initiation [22, 23] toxicant exposure[24], and co-administered products (such as blunts or
85 spliffs) [25]. While other reviews have focused specifically on certain populations such as
86 adolescents and young adults [26]. Lemrye and co [27] in their review, detail the motivation
87 and drivers of co-use including gateway theory and reverse gateway which may have
88 implications in understanding co-use and interventions for cessation.

89 A recent review did explore treatment implications for those that co-use tobacco and
90 cannabis [28], highlighting the challenges of single substance cessation and noting that
91 interventions to address co-use cessation are lacking. Another, important gap in the growing
92 literature is a comprehensive pooled prevalence estimate of tobacco and cannabis co-use.
93 Synthesising existing data including correlates of use [29] is important to understand the
94 extent to which tobacco and cannabis co-use is occurring.

95 There appears to be an increased physiological effect of both substance when used
96 together. The mechanisms underlying the co-use of tobacco and cannabis have been
97 identified as shared genetic factors, environmental factors (peer influences; availability;
98 younger age), and economic factors (lower socio-economic factors)[22]. More recently,
99 another possible factor influencing co-use of tobacco and cannabis is the common route of
100 administration e.g. smoking/ inhalation of both substances[20]. To date, only one review has
101 examined route of administration and only focused on combustible forms of tobacco and

1
2
3 102 cannabis co-use [25]. A synthesis of the literature that includes all possible routes of
4
5 103 administration would fill this gap in the literature.
6

7
8 104 Compared to other substances, cannabis use among tobacco smokers appears to be
9
10 105 more common than the co-use of other substances that occur at a remarkably reduced rate
11
12 106 such as alcohol (33.3-45.7%), cocaine (37.5%-42.9%), stimulants (30-51.7%) and
13
14 107 hallucinogens (35.6-41.7%)[30-32]. The relationship between tobacco and cannabis use is
15
16 108 synergistic in that tobacco use increases cannabis dependence symptoms [20, 33] and
17
18 109 precipitates cannabis relapse [34] and similarly cannabis use increases the likelihood of
19
20 110 nicotine dependence [35] and decreases tobacco cessation [36]. Given this, people who co-
21
22 111 use both tobacco and cannabis are at greater risk for serious for serious health and
23
24 112 psychosocial problems [23]. Co-use is associated with increased risks of toxicant exposure,
25
26 113 poorer physical and mental functioning [25].
27
28
29

30
31 114 Understanding and accounting for current cannabis use among participants involved
32
33 115 in smoking cessation research is important as it may have an impact on the intervention effect
34
35 116 but also the measurement effect. If smokers are recruited into a smoking cessation
36
37 117 intervention but their cannabis use is not addressed, then relapse to tobacco smoking is likely
38
39 118 if they regularly mixed their tobacco with cannabis. Similarly, since cannabis use is detected
40
41 119 in carbon monoxide breath analysis, this method of biochemical verification of tobacco
42
43 120 smoking status may be inaccurate. Therefore, an alternate biochemical method such as serum
44
45 121 or salivary cotinine may be preferable for self-reported tobacco smokers who utilise cannabis
46
47 122 [37].
48
49
50

51 123 Only limited research has described the demographic and clinical characteristics of
52
53 124 people who use both tobacco and cannabis. These studies predominately focussed on young
54
55 125 people who use these substances. Demographic characteristics such as older adolescents[38,
56
57 126 39] another found that people who co-use tobacco and cannabis were younger than tobacco-
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

only users[26], of male gender, and ethnicity. A synthesis of the current literature is critical for the development of an evidence base foundation for developing future randomised controlled trials. This review will provide the first synthesis of the literature and provide pivotal information for specific countries to influence the development of socially and culturally appropriate interventions to further the evidence base.

There is a clear need for an improved understanding as to the co-use of tobacco and cannabis use as this will have practical implications in the design of smoking cessation studies. The tiered approach of assessing co-use as explained by Hindocha and Mclure [40] suggests that consideration of individual-use data as well as co-use data be explored as often there is a lack of nuance in the current methods of collection and analysis. Our review will ask the following questions 1. What is the percentage of smokers who report also using cannabis; 2. What is the nature of co-use of tobacco and cannabis (e.g. mixing together or smoking at different times, including routes of administration); and 3. What is the prevalence of co-use tobacco and cannabis by socio-demographic characteristics (age; gender; country – low and high income; clinical characteristics such as mental health diagnosis and substance use disorder).

METHODS

Study design

We will complete a systematic review examining the prevalence of cannabis use among tobacco smokers generally and by specific socio-demographic and clinical characteristics as well as the nature of the use of these substances (whether concurrently or individually). This review will be conducted in line with the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines with data managed using Stata Statistical Software [41]. This review has been registered with PROSPERO (insert ID

number). Any variations to the originally registered protocol will be submitted as an amendment to PROSPERO and indicated in the review publication.

Study criteria

Study designs: we will include the following study designs: cohort, cross-sectional, observational, baseline studies, national reports. We will exclude published editorials, letters, or conference proceedings (including abstracts), qualitative studies, thesis dissertations, and studies quoting the incidence rate rather than prevalence. Further, we will not use genetic epidemiological studies that report prevalence estimates in family members of individuals who use tobacco and cannabis.

Study populations and participants: Person-level data will be included from any adult population (aged > 18 years and older) including but not limited to educational populations (for example university populations), forensic or correctional populations, treatment seeking populations (people receiving treatment for substance use disorders or mental health conditions, oncological conditions, and other chronic diseases). We will include all routes of administration of tobacco use including alternate nicotine devices such as vaporisers.

Outcomes: We will include studies that report primary data on the prevalence of tobacco and cannabis use (such as total number of participants and percentages or proportions). Given that there is no standard assessment tool of tobacco and cannabis co-use we will include all measures as documented in the literature. For example, separate items that measure cannabis and tobacco use: “Do you currently smoke any tobacco products?” with response options i) yes, at least once a week; ii) yes, less often than once week; iii) no, not at all”; “During the past 30 days, on how many days did you use cannabis?”; “How many times is cannabis used per day on using days”. Co-use has been defined in several recent US studies as the use of both substances within the past 30 days.

Additional eligibility criteria: Only articles that are published in English and that have been published in peer reviewed journals will be included [9].

Search Strategy

The search will be conducted in six databases: CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural Sciences Collection, Scopus, using keywords consistent across all databases and Medical Subject Headings (MeSH) applicable to specific databases. The Medline search terms are outlined in Table 1. Each search term is related to an overarching theme that map largely to the review aims (tobacco use and cannabis use). It should be noted that the search terms have been developed with guidance from the Cochrane Public Health and Tobacco Addiction Group search terms.

Table 1. Search themes and terms

Theme	Search Terms
Study design	Epidemiology
	Cohort stud* OR Cohort analysis
	Cross-sectional stud* OR Cross-section analysis OR Observational analysis OR Prevalence OR Longitudinal
Tobacco use	tobacco OR nicotine OR smok* OR vap* OR cigar*
Cannabis use	cannabis OR cannabinoid* OR marijuana OR weed OR hash*

Screening

Two research assistants (AD, AL) will screen all titles and abstracts using the previously described inclusion criteria overseen by the research academics (ES, JR, TH). Any disagreements will be discussed. If a resolution cannot be found, the senior review author

(BB) will hold a discussion until a resolution is found. The two RAs (AD, AL) completing 50% each. Again, any disagreements will be discussed between the authors and the research assistants. All title, abstract, and full-text data screening will be completed using the Covidence online software v1919 73d6c782.

Data extraction

The team will develop a data extraction form based on the aims of the study. The data extraction form will include: country, year of publication, author, sample size, gender, tobacco use prevalence (lifetime, last 12 months, current), cannabis use prevalence (lifetime, last 12 months, current), co-use prevalence, and routes of administration will be extracted for each paper. The co-use prevalence and calculated 95% confidence intervals (CI) for each estimate will be extracted. For papers reporting measures over time, we will use the prevalence data from the baseline assessment. Two post-doctoral research academics (ES and JR) will extract data from all included publications. Any disagreements will be discussed between all authors. If a resolution cannot be found, the senior review author (BB) will be consulted in order to determine a resolution. Data will be extracted using the Covidence software.

Quality assessment

All cohort, cross-sectional, and case-control studies will be appraised according to Newcastle-Ottawa Quality Assessment Scale for cohort and case-control studies (adapted for cross-sectional studies). Using the tool each study is judged on eight items, that can be categorised into three further groups: 1. The selection of the study groups, 2. The comparability of the groups, and 3. The ascertainment of either the exposure or outcome of interest for case-control or cross-sectional studies respectively. Articles will not be excluded based upon their score on the quality appraisal tool. Quality scores will guide judgement of the methodological quality of the trial and reliability of the findings.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The risk of bias (quality) of all studies meeting the inclusion criteria will be formally assessed by ES, JR, TH. Disagreements will be resolved by discussion with the senior review author (BB). Ratings will be presented in a table and will be used to inform the narrative synthesis.

Assessment of study heterogeneity. Heterogeneity will be examined using visual inspection of box plots, forest plots and using the I2 statistic, Egger’s test will be applied [42]. Where there is evidence of high heterogeneity ($I^2>75\%$), heterogeneity will be explored via subgroup analyses according to population characteristics. If the heterogeneity among the studies is large, a random-effects model will be used to calculate the pooled OR. Otherwise, a fixed-effects model will be applied. We will use a Generalised Linear Model approach, due to methodological concerns with the Freeman–Tukey double-arcsine transformation method [43, 44]. Funnel plots will be generated by statistical software to enable the assessment of publication bias. If publication bias is detected the approximate number of missing studies using the trim-and-fill method [45] will be conducted to provide insight into degree of bias.

Grading the strength of evidence. As recommended by the Cochrane Handbook for Systematic Reviews of Interventions, the overall quality of evidence of the outcomes (tobacco and cannabis co-use prevalence) will be presented using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. This involves a within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias. The overall quality of evidence will be rated at four levels: high, moderate, low and very low. If feasible, the analysis could include individual participant-level meta-analysis.

ES and JR will assess the quality of evidence using the GRADE tool and will present the findings to the fellow authors. The team will discuss the assessment and modify the reported strength of recommendations.

Data synthesis

Depending on the outcome measure employed by studies, pooled estimates by lifetime use, 12-months, and current use will be calculated. If studies have used similar definitions and measures, cannabis prevalence plots including the associated confidence intervals for each study will be presented. If there are national prevalence estimates for cannabis use, we will examine the difference between the study and the national prevalence.

In order to obtain the national smoking prevalence rates, official country statistics websites and the World Health Organisation Health Observatory Data Repository[46] will be consulted and the prevalence data extracted. If the national cannabis prevalence estimates are not available for all included countries for all years in which included studies were completed, we will report this information descriptively in the results section.

Included studies will be examined by socio-demographic and clinical characteristics to provide individual prevalence estimates and distributions. These will include socio-demographic characteristics such as age, gender, country, nationality and Indigeneity. These will also include clinical characteristics such as mental health diagnosis as per the clinical diagnostic handbooks and tools (such as the Diagnostic and Statistical Manual of mental disorders (DSM)[47] or the International Classification of Disease (ICD)[48]) including substance use disorders and clinical populations such as individuals receiving treatment from addiction treatment or mental health services, as well as those with cardiovascular disease, diabetes, or cancer.

Patient and Public Involvement

No patients involved.

Study Status

At the time of submission of this protocol, the authors had completed screening of titles, abstracts, and full-texts, and were beginning data extraction and quality assessment.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

The co-use of tobacco and cannabis and the sub-population who are most likely to co-use these substances are important considerations for intervention planning. This systematic review will provide pooled prevalence estimates of cannabis use among tobacco smokers. This study will report on tobacco and cannabis co-use by specific socio-demographics and clinical characteristics to provide a more in-depth examination and synthesis of the available data. This study will also provide the routes of administration of tobacco and cannabis co-use as this is an important aspect when developing behavioural interventions for cessation.

276 **Abbreviations**

277 DSM, Diagnostic and Statistical Manual of mental disorders

278 ICD, International Classification of Disease

279 GRADE, Grading of Recommendations Assessment, Development, and Evaluation

280 MeSH, Medical Subject Headings

281 PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses

282 RA, Research Assistant

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

283 **Declarations**

284 **Ethics approval and consent to participate:** Ethics approval was not required for this

285 systematic review.

286 **Consent for publication:** Consent was not required for this systematic review

287 **Availability of data and materials:** Not applicable

288 **Competing interests:** The authors declare that they have no competing interests.

289 **Funding:** None to report.

290 **Author contributions:** ES, JR, TH developed the protocol and drafted the manuscript. BB

291 reviewed drafts and provided methodological feedback. All authors approved the final

292 manuscript.

293 **Acknowledgements:** Research Assistance thanks to Alexandra Denham and Alexie Lye for

294 their database assistance and screening abstract reviews.

REFERENCES

1. Anderson, C.L., H. Becher, and V. Winkler, *Tobacco control progress in low and middle income countries in comparison to high income countries*. International journal of environmental research and public health, 2016. **13**(10): p. 1039.
2. Brathwaite, R., et al., *A systematic review of tobacco smoking prevalence and description of tobacco control strategies in Sub-Saharan African countries; 2007 to 2014*. PloS one, 2015. **10**(7): p. e0132401.
3. Centers for Disease Control and Prevention. *Smoking & Tobacco Use: Current Cigarette Smoking among Adults in the United States*. 2020; Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm.
4. Australian Institute of Health and Welfare. *National Drug Strategy Household Survey 2019*. 2019; Available from: <https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2019/contents/table-of-contents>.
5. New Zealand Ministry of Health. *Key Indicators 2020*. 2020; Available from: https://minhealthnz.shinyapps.io/nz-health-survey-2018-19-annual-data-explorer/_w_262e575b/#!/key-indicators.
6. United Kingdom Government. *Adult smoking habits in the UK: 2019*. 2020; Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/adultsmokinghabitsingreatbritain/2019#characteristics-of-current-cigarette-smokers-in-the-uk>.
7. Bonevski, B., et al., *No smoker left behind: it's time to tackle tobacco in Australian priority populations*. Med J Aust, 2017. **207**(4): p. 141-142.
8. Guydish, J., et al., *An international systematic review of smoking prevalence in addiction treatment*. Addiction, 2016. **111**(2): p. 220-230.
9. Dickerson, F., et al., *Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999–2011*. Psychiatric services, 2013. **64**(1): p. 44-50.
10. Arnsten, J.H., et al., *Smoking behavior and interest in quitting among homeless smokers*. Addictive behaviors, 2004. **29**(6): p. 1155-1161.
11. World Health Organization. *The health and social effects of nonmedical cannabis use*. 2021; Available from: https://www.who.int/substance_abuse/publications/msbcannabis.pdf.
12. Degenhardt, L., et al., *The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study*. PloS one, 2013. **8**(10): p. e76635.
13. Weinberger, A.H., et al., *Cigarette smoking quit ratios among adults in the USA with cannabis use and cannabis use disorders, 2002–2016*. Tobacco control, 2020. **29**(1): p. 74-80.
14. Weinberger, A.H., et al., *Trends in cannabis use disorder by cigarette smoking status in the United States, 2002–2016*. Drug and alcohol dependence, 2018. **191**: p. 45-51.
15. Maxwell, J.C. and B. Mendelson, *What do we know about the impact of the laws related to marijuana?* Journal of addiction medicine, 2016. **10**(1): p. 3.
16. Mauro, C.M., et al., *Impact of medical marijuana laws on state-level marijuana use by age and gender, 2004–2013*. Prevention Science, 2019. **20**(2): p. 205-214.
17. Pacek, L.R., P.M. Mauro, and S.S. Martins, *Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity*. Drug and alcohol dependence, 2015. **149**: p. 232-244.
18. Swendsen, J., et al., *Socio-demographic risk factors for alcohol and drug dependence: the 10-year follow-up of the national comorbidity survey*. Addiction, 2009. **104**(8): p. 1346-1355.
19. Zajacova, A., et al., *Changes in health behaviours during early COVID-19 and socio-demographic disparities: a cross-sectional analysis*. Canadian Journal of Public Health, 2020. **111**(6): p. 953-962.

1
2
3 345 20. Agrawal, A. and M.T. Lynskey, *Tobacco and cannabis co-occurrence: does route of*
4 346 *administration matter?* Drug and alcohol dependence, 2009. **99**(1-3): p. 240-247.
5 347 21. Gravelly, S., et al., *International differences in patterns of cannabis use among adult cigarette*
6 348 *smokers: findings from the 2018 ITC Four Country Smoking and Vaping Survey.* International
7 349 Journal of Drug Policy, 2020. **79**: p. 102754.
8 350 22. Agrawal, A., A.J. Budney, and M.T. Lynskey, *The co-occurring use and misuse of cannabis and*
9 351 *tobacco: a review.* Addiction, 2012. **107**(7): p. 1221-1233.
10 352 23. Rabin, R.A. and T.P. George, *A review of co-morbid tobacco and cannabis use disorders:*
11 353 *Possible mechanisms to explain high rates of co-use.* The American journal on addictions,
12 354 2015. **24**(2): p. 105-116.
13 355 24. Meier, E. and D.K. Hatsukami, *A review of the additive health risk of cannabis and tobacco*
14 356 *co-use.* Drug and Alcohol Dependence, 2016. **166**: p. 6-12.
15 357 25. Schauer, G.L., Z.R. Rosenberry, and E.N. Peters, *Marijuana and tobacco co-administration in*
16 358 *blunts, spliffs, and mulled cigarettes: A systematic literature review.* Addictive Behaviors,
17 359 2017. **64**: p. 200-211.
18 360 26. Ramo, D.E., H. Liu, and J.J. Prochaska, *Tobacco and marijuana use among adolescents and*
19 361 *young adults: a systematic review of their co-use.* Clinical psychology review, 2012. **32**(2): p.
20 362 105-121.
21 363 27. Lemyre, A., N. Poliakova, and R.E. Bélanger, *The Relationship Between Tobacco and Cannabis*
22 364 *Use: A Review.* Substance Use & Misuse, 2019. **54**(1): p. 130-145.
23 365 28. McClure, E.A., et al., *Treatment Implications Associated With Cannabis and Tobacco Co-use.*
24 366 Current Addiction Reports, 2020. **7**(4): p. 533-544.
25 367 29. Peters, E.N., A.J. Budney, and K.M. Carroll, *Clinical correlates of co-occurring cannabis and*
26 368 *tobacco use: a systematic review.* Addiction (Abingdon, England), 2012. **107**(8): p. 1404-
27 369 1417.
28 370 30. Barrett, S.P., C. Darredeau, and R.O. Pihl, *Patterns of simultaneous polysubstance use in drug*
29 371 *using university students.* Human Psychopharmacology: Clinical and Experimental, 2006.
30 372 **21**(4): p. 255-263.
31 373 31. Richter, K.P., et al., *A population-based study of cigarette smoking among illicit drug users in*
32 374 *the United States.* Addiction, 2002. **97**(7): p. 861-869.
33 375 32. Correa, J.B., et al., *Co-occurring Use of Cannabis and Tobacco and the Presence of Acute*
34 376 *Respiratory Symptoms among Young Adult Light and Intermittent Smokers.* Substance Use &
35 377 Misuse, 2020. **55**(13): p. 2129-2137.
36 378 33. Ream, G.L., et al., *Smoking tobacco along with marijuana increases symptoms of cannabis*
37 379 *dependence.* Drug and alcohol dependence, 2008. **95**(3): p. 199-208.
38 380 34. Haney, M., et al., *Predictors of marijuana relapse in the human laboratory: robust impact of*
39 381 *tobacco cigarette smoking status.* Biological psychiatry, 2013. **73**(3): p. 242-248.
40 382 35. Okoli, C.T., et al., *Adolescents' self-defined tobacco use status, marijuana use, and tobacco*
41 383 *dependence.* Addictive behaviors, 2008. **33**(11): p. 1491-1499.
42 384 36. Ford, D.E., H.T. Vu, and J.C. Anthony, *Marijuana use and cessation of tobacco smoking in*
43 385 *adults from a community sample.* Drug and alcohol dependence, 2002. **67**(3): p. 243-248.
44 386 37. Van Vunakis, H., et al., *Relative sensitivity and specificity of salivary and serum cotinine in*
45 387 *identifying tobacco-smoking status of self-reported nonsmokers and smokers of tobacco*
46 388 *and/or marijuana.* Archives of Environmental Health: An International Journal, 1989. **44**(1):
47 389 p. 53-58.
48 390 38. Suris, J.-C., et al., *Some go without a cigarette: characteristics of cannabis users who have*
49 391 *never smoked tobacco.* Archives of pediatrics & adolescent medicine, 2007. **161**(11): p. 1042-
50 392 1047.
51 393 39. Victoir, A., et al., *Association of substance-use behaviours and their social-cognitive*
52 394 *determinants in secondary school students.* Health education research, 2007. **22**(1): p. 81-94.
53
54
55
56
57
58
59
60

- 395 40. Hindocha, C. and E.A. McClure, *Unknown population-level harms of cannabis and tobacco*
396 *co-use: if you don't measure it, you can't manage it*. *Addiction*, 2021. **116**(7): p. 1622-1630.
- 397 41. StataCorp, L., *Stata statistical software: Release 15 (2017)*. College Station, TX: StataCorp LP,
398 2017.
- 399 42. Egger, M., et al., *Bias in meta-analysis detected by a simple, graphical test*. *Bmj*, 1997.
400 **315**(7109): p. 629-634.
- 401 43. Schwarzer, G., et al., *Seriously misleading results using inverse of Freeman-Tukey double*
402 *arcsine transformation in meta-analysis of single proportions*. *Res Synth Methods*, 2019.
403 **10**(3): p. 476-483.
- 404 44. Lin, L. and C. Xu, *Arcsine-based transformations for meta-analysis of proportions: Pros, cons,*
405 *and alternatives*. *Health Science Reports*, 2020. **3**(3): p. e178.
- 406 45. Duval, S. and R. Tweedie, *Trim and fill: A simple funnel-plot-based method of testing and*
407 *adjusting for publication bias in meta-analysis*. *Biometrics*, 2000. **56**(2): p. 455-63.
- 408 46. World Health Organization, *Global health observatory data repository*. 2013.
- 409 47. Association, A.P., *Diagnostic and statistical manual of mental disorders (DSM-5®)*. 2013:
410 American Psychiatric Pub.
- 411 48. World Health Organization, *International Classification of Disease—Ninth revision(ICD-9)*.
412 *Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire*, 1988. **63**(45): p.
413 343-344.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page #
ADMINISTRATIVE INFORMATION			
Title:			1
Identification	1a	Identify the report as a protocol of a systematic review	
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
	3b	Describe contributions of protocol authors and identify the guarantor of the review	1 &14
Contributions			
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	14
Sponsor	5b	Provide name for the review funder and/or sponsor	14
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	14
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6-7
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	7-8
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	8

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	9
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	9-10
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	9-10
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	9-10
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	11
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	11
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	10
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	N/A
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	N/A
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11-12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	11
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	N/A
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	11

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

The prevalence of cannabis use among tobacco smokers: A systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050681.R2
Article Type:	Protocol
Date Submitted by the Author:	29-Mar-2022
Complete List of Authors:	Skelton, Eliza; The University of Newcastle Faculty of Health and Medicine Rich, Jane; The University of Newcastle Faculty of Health and Medicine Handley, Tonelle; University of Newcastle, Bonevski, Billie; Flinders University College of Medicine and Public Health
Primary Subject Heading:	Addiction
Secondary Subject Heading:	Public health, Smoking and tobacco
Keywords:	PUBLIC HEALTH, EPIDEMIOLOGY, Substance misuse < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title

The prevalence of cannabis use among tobacco smokers: A systematic review protocol

Authors, Affiliations, highest academic, qualification and emails

Eliza Skelton¹, PhD (Psychiatry), Eliza.Skelton@newcastle.edu.au

Jane Rich¹ PhD (Public Health), Jane.Rich@newcastle.edu.au

Tonelle Handley¹ PhD (Psychiatry), Tonelle.Handley@newcastle.edu.au

Billie Bonevski² PhD (Behavioural Science), billie.bonevski@flinders.edu.au

Institutional Affiliations

¹ The University of Newcastle, Faculty of Health and Medicine, School of Medicine and Public Health, 1 University Drive, Callaghan, NSW 2308, Australia.

² Flinders University, Bedford Park, South Australia, 5042

***Corresponding author:** Prof Billie Bonevski PhD (Behavioural Science), billie.bonevski@flinders.edu.au College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042.

Manuscript word count: 2581

Manuscript number of reference: 37

Tables: 1

Figures: 0

Supplementary Tables and Figures: 0

Abstract

Introduction: Understanding the prevalence of cannabis use among tobacco smokers has important implications for research in terms of intervention effectiveness and measurement in smoking cessation trials. The co-use of these substances also has important implications for health service planning, specifically ensuring appropriate and adequate clinical treatment. To date there have been no synthesis of the literature on the prevalence of tobacco and cannabis co-use in adult clinical populations. Improved understanding of the current prevalence, route of administration, and specific subpopulations with the highest rates of tobacco and cannabis co-use will support future intervention development. We aim to provide a pooled estimate of the percentage of smokers who report using cannabis and to examine the prevalence of co-use by socio-demographic characteristics.

Methods and Analysis: We will conduct a systematic review using six scientific databases with published articles from 2000 -2022 inclusive (CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural Sciences Collection, Scopus). Peer-reviewed journal articles published in English that report on tobacco and cannabis use will be included. Rates of co-use (simultaneous or sequentially) and routes of administration will be assessed. Use in populations groups will be described. Quality assessments will be conducted for all included studies. Data will be synthesised using a narrative approach. This study will be conducted from June 2022 until the end of August 2022.

Ethics and Dissemination: This review is based upon previously published data and therefore ethical approval or written informed consent will not be required. It is the intention of the research team to disseminate the results of the systematic review as a peer reviewed publication and conference presentations.

Systematic review registration: CRD42020194051.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

45 **Keywords:** Public Health, Epidemiology, Substance Misuse

For peer review only

Strengths and limitations:

- Utilising the gold standard or meta-analysis, the proposed review will collate multiple studies to provide the first pooled prevalence of tobacco and cannabis co-use.
- This review will also provide important information on the sub-groups that require targeted intervention.
- There are several limitations that need to be noted, the first, is publication bias and the second is that if the included studies measures are too heterogeneous, we will not be able to complete a meta-analysis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Tobacco smoking continues to be a leading cause of preventable disease and death. An estimated 1.1 billion people continue to smoke tobacco. Over the past three decades the prevalence of tobacco smoking has been increasing in low- and middle-income countries (LMIC) [1] where an inverse relationship is seen in high income countries (HIC) where significant declines are noted. For example, in LMIC, the adult smoking prevalence rate has increased from 12.4% to 22.8% in Rwanda, from 33.8% to 39.5% in Indonesia, and from 16% to 40.4% in Zambia[2]. While in HIC, the tobacco smoking prevalence has reduced from 30.1% to 13.7% in the US[3], from 31% to 14.0% in Australia[4], 30% to 14.2% in New Zealand[5], and 33% to 14.1% in the United Kingdom[6]. The decline in the prevalence of tobacco smoking appears to be less apparent among specific sub-populations in HIC[7]. People who have a substance use disorder or are in treatment for substance misuse[8], people with a severe mental illness[9], people who are homeless or at risk of homelessness[10] are found to have smoking rates 2-6 times higher than the general population.

Cannabis is another commonly utilised substance[11]. Global estimates suggest that the number of cannabis users has increased in many countries, as has the treatment for cannabis use disorder[12]. Changing regulatory environments and the legalisation of cannabis in some countries, and decreasing perceptions of risk associated with cannabis use[13, 14], have been viewed to contribute to this recently increase in use[15-17]. Other contributors to the increased use of cannabis include socio-demographic and environmental risk factors [18] including the COVID-19 pandemic [19]. These factors may differ in between LMIC compared to high-income countries yet no review to date has examine this relationship.

Co-use can refer to concurrent use of both tobacco and cannabis, individually (sequentially), and to co-administration, or the use of the two substances at the same time, eg cannabis and tobacco leaf mixed within roll-your-own cigarettes (concurrent)[20]. Patterns of

1
2
3 80 tobacco and cannabis co-use appear to differ by country. A 2018 International Tobacco
4
5 81 Control Survey identified that Canada, followed by the US (29.1%), England (21.6%), and
6
7 82 Australia (21.4%) had the highest rates of tobacco and cannabis co-use [21]. There are
8
9 83 limited studies examining tobacco and cannabis co-use in LMIC. Tobacco and cannabis co-
10
11 84 use is often missed in population prevalence surveys[13].
12
13

14
15 85 Previous reviews on tobacco and cannabis co-use have examined mechanisms of
16
17 86 initiation [22, 23] toxicant exposure[24], and co-administered products (such as blunts or
18
19 87 spliffs) [25]. While other reviews have focused specifically on certain populations such as
20
21 88 adolescents and young adults [26]. Lemrye and co [27] in their review, detail the motivation
22
23 89 and drivers of co-use including gateway theory and reverse gateway which may have
24
25 90 implications in understanding co-use and interventions for cessation.
26
27

28
29 91 A recent review did explore treatment implications for those that co-use tobacco and
30
31 92 cannabis [28], highlighting the challenges of single substance cessation and noting that
32
33 93 interventions to address co-use cessation are lacking. Another, important gap in the growing
34
35 94 literature is a comprehensive pooled prevalence estimate of tobacco and cannabis co-use.
36
37 95 Synthesising existing data including correlates of use [29] is important to understand the
38
39 96 extent to which tobacco and cannabis co-use is occurring.
40
41

42
43 97 There appears to be an increased physiological effect of both substance when used
44
45 98 together. The mechanisms underlying the co-use of tobacco and cannabis have been
46
47 99 identified as shared genetic factors, environmental factors (peer influences; availability;
48
49 100 younger age), and economic factors (lower socio-economic factors)[22]. More recently,
50
51 101 another possible factor influencing co-use of tobacco and cannabis is the common route of
52
53 102 administration e.g. smoking/ inhalation of both substances[20]. To date, only one review has
54
55 103 examined route of administration and only focused on combustible forms of tobacco and
56
57
58
59
60

104 cannabis co-use [25]. A synthesis of the literature that includes all possible routes of
105 administration would fill this gap in the literature.

106 Compared to other substances, cannabis use among tobacco smokers appears to be
107 more common than the co-use of other substances that occur at a remarkably reduced rate
108 such as alcohol (33.3-45.7%), cocaine (37.5%-42.9%), stimulants (30-51.7%) and
109 hallucinogens (35.6-41.7%)[30-32]. The relationship between tobacco and cannabis use is
110 synergistic in that tobacco use increases cannabis dependence symptoms [20, 33] and
111 precipitates cannabis relapse [34] and similarly cannabis use increases the likelihood of
112 nicotine dependence [35] and decreases tobacco cessation [36]. Given this, people who co-
113 use both tobacco and cannabis are at greater risk for serious for serious health and
114 psychosocial problems [23]. Co-use is associated with increased risks of toxicant exposure,
115 poorer physical and mental functioning [25].

116 Understanding and accounting for current cannabis use among participants involved
117 in smoking cessation research is important as it may have an impact on the intervention effect
118 but also the measurement effect. If smokers are recruited into a smoking cessation
119 intervention but their cannabis use is not addressed, then relapse to tobacco smoking is likely
120 if they regularly mixed their tobacco with cannabis. Similarly, since cannabis use is detected
121 in carbon monoxide breath analysis, this method of biochemical verification of tobacco
122 smoking status may be inaccurate. Therefore, an alternate biochemical method such as serum
123 or salivary cotinine may be preferable for self-reported tobacco smokers who utilise cannabis
124 [37].

125 Only limited research has described the demographic and clinical characteristics of
126 people who use both tobacco and cannabis. These studies predominately focussed on young
127 people who use these substances. Demographic characteristics such as older adolescents[38,
128 39] another found that people who co-use tobacco and cannabis were younger than tobacco-

only users[26], of male gender, and ethnicity. A synthesis of the current literature is critical for the development of an evidence base foundation for developing future randomised controlled trials. This review will provide the first synthesis of the literature and provide pivotal information for specific countries to influence the development of socially and culturally appropriate interventions to further the evidence base.

There is a clear need for an improved understanding as to the co-use of tobacco and cannabis use as this will have practical implications in the design of smoking cessation studies. The tiered approach of assessing co-use as explained by Hindocha and McLure [40] suggests that consideration of individual-use data as well as co-use data be explored as often there is a lack of nuance in the current methods of collection and analysis. Our review will ask the following questions 1. What is the percentage of smokers who report also using cannabis; 2. What is the nature of co-use of tobacco and cannabis (e.g. mixing together or smoking at different times, including routes of administration); and 3. What is the prevalence of co-use tobacco and cannabis by socio-demographic characteristics (age; gender; country – low and high income; clinical characteristics such as mental health diagnosis and substance use disorder).

METHODS

Study design

We will complete a systematic review examining the prevalence of cannabis use among tobacco smokers generally and by specific socio-demographic and clinical characteristics as well as the nature of the use of these substances (whether concurrently or individually). This review will be conducted in line with the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines with data managed using Stata Statistical Software [41]. This review has been registered with PROSPERO (insert ID

number). Any variations to the originally registered protocol will be submitted as an amendment to PROSPERO and indicated in the review publication.

Study criteria

Study designs: we will include the following study designs: cohort, cross-sectional, observational, baseline studies, national reports. We will exclude published editorials, letters, or conference proceedings (including abstracts), qualitative studies, thesis dissertations, and studies quoting the incidence rate rather than prevalence. Further, we will not use genetic epidemiological studies that report prevalence estimates in family members of individuals who use tobacco and cannabis. This study will be conducted from June 2022 until the end of August 2022.

Study populations and participants: Person-level data will be included from any adult population (aged > 18 years and older) including but not limited to educational populations (for example university populations), forensic or correctional populations, treatment seeking populations (people receiving treatment for substance use disorders or mental health conditions, oncological conditions, and other chronic diseases). We will include all routes of administration of tobacco use including alternate nicotine devices such as vaporisers.

Outcomes: We will include studies that report primary data on the prevalence of tobacco and cannabis use (such as total number of participants and percentages or proportions). Given that there is no standard assessment tool of tobacco and cannabis co-use we will include all measures as documented in the literature. For example, separate items that measure cannabis and tobacco use: “Do you currently smoke any tobacco products?” with response options i) yes, at least once a week; ii) yes, less often than once week; iii) no, not at all”; “During the past 30 days, on how many days did you use cannabis?”; “How many times

is cannabis used per day on using days". Co-use has been defined in several recent US studies as the use of both substances within the past 30 days.

Additional eligibility criteria: Only articles that are published in English and that have been published in peer reviewed journals will be included [9].

Ethics and Dissemination: This review is based upon previously published data and therefore ethical approval or written informed consent will not be required. It is the intention of the research team to disseminate the results of the systematic review as a peer reviewed publication and conference presentations.

Search Strategy

The search will be conducted in six databases with published articles from 2000 -2022 inclusive: CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural Sciences Collection, Scopus, using keywords consistent across all databases and Medical Subject Headings (MeSH) applicable to specific databases. The Medline search terms are outlined in Table 1. Each search term is related to an overarching theme that map largely to the review aims (tobacco use and cannabis use). It should be noted that the search terms have been developed with guidance from the Cochrane Public Health and Tobacco Addiction Group search terms.

Table 1. Search themes and terms

Theme	Search Terms	Limitations
Study design	Epidemiology Cohort stud* OR Cohort analysis	2000-2022

	Cross-sectional stud* OR Cross-section analysis OR Observational analysis OR Prevalence OR Longitudinal	
Tobacco use	tobacco OR nicotine OR smok* OR vap* OR cigar*	Exclude clinical trials
Cannabis use	cannabis OR cannabinoid* OR marijuana OR weed OR hash*	

Screening

Two research assistants (AD, AL) will screen all titles and abstracts using the previously described inclusion criteria overseen by the research academics (ES, JR, TH). Any disagreements will be discussed. If a resolution cannot be found, the senior review author (BB) will hold a discussion until a resolution is found. The two RAs (AD, AL) completing 50% each. Again, any disagreements will be discussed between the authors and the research assistants. All title, abstract, and full-text data screening will be completed using the Covidence online software v1919 73d6c782.

Data extraction

The team will develop a data extraction form based on the aims of the study. The data extraction form will include: country, year of publication, author, sample size, gender, tobacco use prevalence (lifetime, last 12 months, current), cannabis use prevalence (lifetime, last 12 months, current), co-use prevalence, and routes of administration will be extracted for each paper. The co-use prevalence and calculated 95% confidence intervals (CI) for each estimate will be extracted. For papers reporting measures over time, we will use the

prevalence data from the baseline assessment. Two post-doctoral research academics (ES and JR) will extract data from all included publications. Any disagreements will be discussed between all authors. If a resolution cannot be found, the senior review author (BB) will be consulted in order to determine a resolution. Data will be extracted using the Covidence software.

Quality assessment

All cohort, cross-sectional, and case-control studies will be appraised according to Newcastle-Ottawa Quality Assessment Scale for cohort and case-control studies (adapted for cross-sectional studies). Using the tool each study is judged on eight items, that can be categorised into three further groups: 1. The selection of the study groups, 2. The comparability of the groups, and 3. The ascertainment of either the exposure or outcome of interest for case-control or cross-sectional studies respectively. Articles will not be excluded based upon their score on the quality appraisal tool. Quality scores will guide judgement of the methodological quality of the trial and reliability of the findings.

The risk of bias (quality) of all studies meeting the inclusion criteria will be formally assessed by ES, JR, TH. Disagreements will be resolved by discussion with the senior review author (BB). Ratings will be presented in a table and will be used to inform the narrative synthesis.

Assessment of study heterogeneity. Heterogeneity will be examined using visual inspection of box plots, forest plots and using the I² statistic, Egger's test will be applied [42]. Where there is evidence of high heterogeneity (I²>75%), heterogeneity will be explored via subgroup analyses according to population characteristics. If the heterogeneity among the studies is large, a random-effects model will be used to calculate the pooled OR. Otherwise, a fixed-effects model will be applied. We will use a Generalised Linear Model approach, due to methodological concerns with the Freeman–Tukey double-arcsine transformation method

[43, 44]. Funnel plots will be generated by statistical software to enable the assessment of publication bias. If publication bias is detected the approximate number of missing studies using the trim-and-fill method [45] will be conducted to provide insight into degree of bias.

Grading the strength of evidence. As recommended by the Cochrane Handbook for Systematic Reviews of Interventions, the overall quality of evidence of the outcomes (tobacco and cannabis co-use prevalence) will be presented using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. This involves a within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias. The overall quality of evidence will be rated at four levels: high, moderate, low and very low. If feasible, the analysis could include individual participant-level meta-analysis.

ES and JR will assess the quality of evidence using the GRADE tool and will present the findings to the fellow authors. The team will discuss the assessment and modify the reported strength of recommendations.

Data synthesis

Depending on the outcome measure employed by studies, pooled estimates by lifetime use, 12-months, and current use will be calculated. If studies have used similar definitions and measures, cannabis prevalence plots including the associated confidence intervals for each study will be presented. If there are national prevalence estimates for cannabis use, we will examine the difference between the study and the national prevalence.

In order to obtain the national smoking prevalence rates, official country statistics websites and the World Health Organisation Health Observatory Data Repository[46] will be consulted and the prevalence data extracted. If the national cannabis prevalence estimates are not available for all included countries for all years in which included studies were completed, we will report this information descriptively in the results section.

Included studies will be examined by socio-demographic and clinical characteristics to provide individual prevalence estimates and distributions. These will include socio-demographic characteristics such as age, gender, country, nationality and Indigeneity. These will also include clinical characteristics such as mental health diagnosis as per the clinical diagnostic handbooks and tools (such as the Diagnostic and Statistical Manual of mental disorders (DSM)[47] or the International Classification of Disease (ICD)[48]) including substance use disorders and clinical populations such as individuals receiving treatment from addiction treatment or mental health services, as well as those with cardiovascular disease, diabetes, or cancer.

Patient and Public Involvement

No patients involved.

Study Status

At the time of submission of this protocol, the authors had completed screening of titles, abstracts, and full-texts, and were beginning data extraction and quality assessment.

DISCUSSION

The co-use of tobacco and cannabis and the sub-population who are most likely to co-use these substances are important considerations for intervention planning. This systematic review will provide pooled prevalence estimates of cannabis use among tobacco smokers. This study will report on tobacco and cannabis co-use by specific socio-demographics and clinical characteristics to provide a more in-depth examination and synthesis of the available data. This study will also provide the routes of administration of tobacco and cannabis co-use as this is an important aspect when developing behavioural interventions for cessation. As with all research, naturally there are limitations to be considered. Firstly, is publication bias, it is likely that given the rigorous nature of predetermined search strategies some publications may be missed from this review. Secondly, is that if the included studies measures are too

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

288 heterogeneous, a complete a meta-analysis may not be feasible. However, in utilising the gold
289 standard of meta-analysis, the proposed review will collate multiple studies to provide the
290 first pooled prevalence of tobacco and cannabis co-use. This review will also provide
291 important information on the sub-groups that require targeted intervention. As such, the
292 benefits of this review will outweigh any such methodological limitations.

293
294
295

For peer review only

296 **Abbreviations**

297 DSM, Diagnostic and Statistical Manual of mental disorders

298 ICD, International Classification of Disease

299 GRADE, Grading of Recommendations Assessment, Development, and Evaluation

300 MeSH, Medical Subject Headings

301 PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses

302 RA, Research Assistant

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

303 **Declarations**

304 **Ethics approval and consent to participate:** Ethics approval was not required for this

305 systematic review.

306 **Consent for publication:** Consent was not required for this systematic review

307 **Availability of data and materials:** Not applicable

308 **Competing interests:** The authors declare that they have no competing interests.

309 **Funding:** None to report.

310 **Author contributions:** ES, JR, TH developed the protocol and drafted the manuscript. BB

311 reviewed drafts and provided methodological feedback. All authors approved the final

312 manuscript.

313 **Acknowledgements:** Research Assistance thanks to Alexandra Denham and Alexie Lye for

314 their database assistance and screening abstract reviews.

REFERENCES

1. Anderson, C.L., H. Becher, and V. Winkler, *Tobacco control progress in low and middle income countries in comparison to high income countries*. International journal of environmental research and public health, 2016. **13**(10): p. 1039.
2. Brathwaite, R., et al., *A systematic review of tobacco smoking prevalence and description of tobacco control strategies in Sub-Saharan African countries; 2007 to 2014*. PloS one, 2015. **10**(7): p. e0132401.
3. Centers for Disease Control and Prevention. *Smoking & Tobacco Use: Current Cigarette Smoking among Adults in the United States*. 2020; Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm.
4. Australian Institute of Health and Welfare. *National Drug Strategy Household Survey 2019*. 2019; Available from: <https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2019/contents/table-of-contents>.
5. New Zealand Ministry of Health. *Key Indicators 2020*. 2020; Available from: https://minhealthnz.shinyapps.io/nz-health-survey-2018-19-annual-data-explorer/_w_262e575b/#!/key-indicators.
6. United Kingdom Government. *Adult smoking habits in the UK: 2019*. 2020; Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/adultsmokinghabitsingreatbritain/2019#characteristics-of-current-cigarette-smokers-in-the-uk>.
7. Bonevski, B., et al., *No smoker left behind: it's time to tackle tobacco in Australian priority populations*. Med J Aust, 2017. **207**(4): p. 141-142.
8. Guydish, J., et al., *An international systematic review of smoking prevalence in addiction treatment*. Addiction, 2016. **111**(2): p. 220-230.
9. Dickerson, F., et al., *Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999–2011*. Psychiatric services, 2013. **64**(1): p. 44-50.
10. Arnsten, J.H., et al., *Smoking behavior and interest in quitting among homeless smokers*. Addictive behaviors, 2004. **29**(6): p. 1155-1161.
11. World Health Organization. *The health and social effects of nonmedical cannabis use*. 2021; Available from: https://www.who.int/substance_abuse/publications/msbcannabis.pdf.
12. Degenhardt, L., et al., *The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study*. PloS one, 2013. **8**(10): p. e76635.
13. Weinberger, A.H., et al., *Cigarette smoking quit ratios among adults in the USA with cannabis use and cannabis use disorders, 2002–2016*. Tobacco control, 2020. **29**(1): p. 74-80.
14. Weinberger, A.H., et al., *Trends in cannabis use disorder by cigarette smoking status in the United States, 2002–2016*. Drug and alcohol dependence, 2018. **191**: p. 45-51.
15. Maxwell, J.C. and B. Mendelson, *What do we know about the impact of the laws related to marijuana?* Journal of addiction medicine, 2016. **10**(1): p. 3.
16. Mauro, C.M., et al., *Impact of medical marijuana laws on state-level marijuana use by age and gender, 2004–2013*. Prevention Science, 2019. **20**(2): p. 205-214.
17. Pacek, L.R., P.M. Mauro, and S.S. Martins, *Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity*. Drug and alcohol dependence, 2015. **149**: p. 232-244.
18. Swendsen, J., et al., *Socio-demographic risk factors for alcohol and drug dependence: the 10-year follow-up of the national comorbidity survey*. Addiction, 2009. **104**(8): p. 1346-1355.
19. Zajacova, A., et al., *Changes in health behaviours during early COVID-19 and socio-demographic disparities: a cross-sectional analysis*. Canadian Journal of Public Health, 2020. **111**(6): p. 953-962.

1
2
3 365 20. Agrawal, A. and M.T. Lynskey, *Tobacco and cannabis co-occurrence: does route of*
4 366 *administration matter?* Drug and alcohol dependence, 2009. **99**(1-3): p. 240-247.
5 367 21. Gravelly, S., et al., *International differences in patterns of cannabis use among adult cigarette*
6 368 *smokers: findings from the 2018 ITC Four Country Smoking and Vaping Survey.* International
7 369 *Journal of Drug Policy*, 2020. **79**: p. 102754.
8 370 22. Agrawal, A., A.J. Budney, and M.T. Lynskey, *The co-occurring use and misuse of cannabis and*
9 371 *tobacco: a review.* Addiction, 2012. **107**(7): p. 1221-1233.
10 372 23. Rabin, R.A. and T.P. George, *A review of co-morbid tobacco and cannabis use disorders:*
11 373 *Possible mechanisms to explain high rates of co-use.* The American journal on addictions,
12 374 2015. **24**(2): p. 105-116.
13 375 24. Meier, E. and D.K. Hatsukami, *A review of the additive health risk of cannabis and tobacco*
14 376 *co-use.* Drug and Alcohol Dependence, 2016. **166**: p. 6-12.
15 377 25. Schauer, G.L., Z.R. Rosenberry, and E.N. Peters, *Marijuana and tobacco co-administration in*
16 378 *blunts, spliffs, and mulled cigarettes: A systematic literature review.* Addictive Behaviors,
17 379 2017. **64**: p. 200-211.
18 380 26. Ramo, D.E., H. Liu, and J.J. Prochaska, *Tobacco and marijuana use among adolescents and*
19 381 *young adults: a systematic review of their co-use.* Clinical psychology review, 2012. **32**(2): p.
20 382 105-121.
21 383 27. Lemyre, A., N. Poliakova, and R.E. Bélanger, *The Relationship Between Tobacco and Cannabis*
22 384 *Use: A Review.* Substance Use & Misuse, 2019. **54**(1): p. 130-145.
23 385 28. McClure, E.A., et al., *Treatment Implications Associated With Cannabis and Tobacco Co-use.*
24 386 *Current Addiction Reports*, 2020. **7**(4): p. 533-544.
25 387 29. Peters, E.N., A.J. Budney, and K.M. Carroll, *Clinical correlates of co-occurring cannabis and*
26 388 *tobacco use: a systematic review.* Addiction (Abingdon, England), 2012. **107**(8): p. 1404-
27 389 1417.
28 390 30. Barrett, S.P., C. Darredeau, and R.O. Pihl, *Patterns of simultaneous polysubstance use in drug*
29 391 *using university students.* Human Psychopharmacology: Clinical and Experimental, 2006.
30 392 **21**(4): p. 255-263.
31 393 31. Richter, K.P., et al., *A population-based study of cigarette smoking among illicit drug users in*
32 394 *the United States.* Addiction, 2002. **97**(7): p. 861-869.
33 395 32. Correa, J.B., et al., *Co-occurring Use of Cannabis and Tobacco and the Presence of Acute*
34 396 *Respiratory Symptoms among Young Adult Light and Intermittent Smokers.* Substance Use &
35 397 *Misuse*, 2020. **55**(13): p. 2129-2137.
36 398 33. Ream, G.L., et al., *Smoking tobacco along with marijuana increases symptoms of cannabis*
37 399 *dependence.* Drug and alcohol dependence, 2008. **95**(3): p. 199-208.
38 400 34. Haney, M., et al., *Predictors of marijuana relapse in the human laboratory: robust impact of*
39 401 *tobacco cigarette smoking status.* Biological psychiatry, 2013. **73**(3): p. 242-248.
40 402 35. Okoli, C.T., et al., *Adolescents' self-defined tobacco use status, marijuana use, and tobacco*
41 403 *dependence.* Addictive behaviors, 2008. **33**(11): p. 1491-1499.
42 404 36. Ford, D.E., H.T. Vu, and J.C. Anthony, *Marijuana use and cessation of tobacco smoking in*
43 405 *adults from a community sample.* Drug and alcohol dependence, 2002. **67**(3): p. 243-248.
44 406 37. Van Vunakis, H., et al., *Relative sensitivity and specificity of salivary and serum cotinine in*
45 407 *identifying tobacco-smoking status of self-reported nonsmokers and smokers of tobacco*
46 408 *and/or marijuana.* Archives of Environmental Health: An International Journal, 1989. **44**(1):
47 409 p. 53-58.
48 410 38. Suris, J.-C., et al., *Some go without a cigarette: characteristics of cannabis users who have*
49 411 *never smoked tobacco.* Archives of pediatrics & adolescent medicine, 2007. **161**(11): p. 1042-
50 412 1047.
51 413 39. Victoir, A., et al., *Association of substance-use behaviours and their social-cognitive*
52 414 *determinants in secondary school students.* Health education research, 2007. **22**(1): p. 81-94.
53
54
55
56
57
58
59
60

40. Hindocha, C. and E.A. McClure, *Unknown population-level harms of cannabis and tobacco co-use: if you don't measure it, you can't manage it*. *Addiction*, 2021. **116**(7): p. 1622-1630.
41. StataCorp, L., *Stata statistical software: Release 15 (2017)*. College Station, TX: StataCorp LP, 2017.
42. Egger, M., et al., *Bias in meta-analysis detected by a simple, graphical test*. *Bmj*, 1997. **315**(7109): p. 629-634.
43. Schwarzer, G., et al., *Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions*. *Res Synth Methods*, 2019. **10**(3): p. 476-483.
44. Lin, L. and C. Xu, *Arcsine-based transformations for meta-analysis of proportions: Pros, cons, and alternatives*. *Health Science Reports*, 2020. **3**(3): p. e178.
45. Duval, S. and R. Tweedie, *Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis*. *Biometrics*, 2000. **56**(2): p. 455-63.
46. World Health Organization, *Global health observatory data repository*. 2013.
47. Association, A.P., *Diagnostic and statistical manual of mental disorders (DSM-5®)*. 2013: American Psychiatric Pub.
48. World Health Organization, *International Classification of Disease—Ninth revision(ICD-9)*. *Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire*, 1988. **63**(45): p. 343-344.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page #
ADMINISTRATIVE INFORMATION			
Title:			1
Identification	1a	Identify the report as a protocol of a systematic review	
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
	3b	Describe contributions of protocol authors and identify the guarantor of the review	1 &14
Contributions			
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	14
Sponsor	5b	Provide name for the review funder and/or sponsor	14
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	14
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6-7
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	7-8
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	8

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	9
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	9-10
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	9-10
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	9-10
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	11
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	11
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	10
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	N/A
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	N/A
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11-12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	11
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	N/A
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	11

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.